NO943388L - Selective change of antibody immunogenicity - Google Patents

Selective change of antibody immunogenicity

Info

Publication number
NO943388L
NO943388L NO943388A NO943388A NO943388L NO 943388 L NO943388 L NO 943388L NO 943388 A NO943388 A NO 943388A NO 943388 A NO943388 A NO 943388A NO 943388 L NO943388 L NO 943388L
Authority
NO
Norway
Prior art keywords
idiotype
immunogenicity
response
antibody
selective change
Prior art date
Application number
NO943388A
Other languages
Norwegian (no)
Other versions
NO943388D0 (en
Inventor
Thomas R Sykes
Mark Reddish
Richard P Baum
Antoine A Noujaim
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Publication of NO943388D0 publication Critical patent/NO943388D0/en
Publication of NO943388L publication Critical patent/NO943388L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1078—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an immunoglobulin, i.e. being an (anti)-anti-idiotypic antibody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • C07K16/4258—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig
    • C07K16/4266—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig against anti-receptor Ig against anti-tumor receptor Ig
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Den foreliggende oppfinnelsen vedrører en enkel frem- gangsmåte for modifikasjon av f.eks. anti-TAA antistoffer som forandrer deres immunogenisitet slik at deres evne til å indusere en anti-isotyp respons selektivt reduseres, mens de forblir istand til å utløse en anti-idiotyp respons. Det sistnevnte er av potensiell immunoterapeutisk verdi, dvs. ved aktivering av idiotyp-anti-idiotyp nettverket. Denne modifikasjonen dannes som en kontrollert og delvis reduksjon av antistoffet, og effektorområder er bevart. Oppfinnelsen bør tillate gjentatte injeksjoner (for diagnose og terapi) og redusere HAMA interferens i serodiagnostiske målinger.The present invention relates to a simple method of modifying e.g. anti-TAA antibodies that alter their immunogenicity so as to selectively reduce their ability to induce an anti-isotype response, while remaining capable of triggering an anti-idiotype response. The latter is of potential immunotherapeutic value, i.e., by activating the idiotype-anti-idiotype network. This modification is formed as a controlled and partial reduction of the antibody, and effector regions are conserved. The invention should allow repeated injections (for diagnosis and therapy) and reduce HAMA interference in serodiagnostic measurements.

NO943388A 1992-03-18 1994-09-12 Selective change of antibody immunogenicity NO943388L (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85360592A 1992-03-18 1992-03-18
PCT/CA1993/000110 WO1993018792A1 (en) 1992-03-18 1993-03-18 Selective alteration of antibody immunogenicity

Publications (2)

Publication Number Publication Date
NO943388D0 NO943388D0 (en) 1994-09-12
NO943388L true NO943388L (en) 1994-11-18

Family

ID=25316485

Family Applications (1)

Application Number Title Priority Date Filing Date
NO943388A NO943388L (en) 1992-03-18 1994-09-12 Selective change of antibody immunogenicity

Country Status (7)

Country Link
EP (1) EP0631507A1 (en)
JP (1) JPH07504668A (en)
AU (1) AU3881593A (en)
CA (1) CA2131621A1 (en)
FI (1) FI944314A0 (en)
NO (1) NO943388L (en)
WO (1) WO1993018792A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121041A0 (en) 1997-06-09 1997-11-20 Yeda Res & Dev Immunogenic compositions for induction of anti-tumor immunity
JP2002504154A (en) * 1997-06-17 2002-02-05 アルタレックス コーポレイション Therapeutic compositions and methods of treatment
WO2011075861A1 (en) 2009-12-23 2011-06-30 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661586A (en) * 1981-11-17 1987-04-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies
US4816249A (en) * 1981-11-17 1989-03-28 The Board Of Trustees Of The Leland Stanford Junior University Monoclonal anti-idiotype antibodies

Also Published As

Publication number Publication date
NO943388D0 (en) 1994-09-12
JPH07504668A (en) 1995-05-25
AU3881593A (en) 1993-10-21
CA2131621A1 (en) 1993-09-30
EP0631507A1 (en) 1995-01-04
FI944314A (en) 1994-09-16
FI944314A0 (en) 1994-09-16
WO1993018792A1 (en) 1993-09-30

Similar Documents

Publication Publication Date Title
FI934861A0 (en) Foerfarande Foer framstaellning av 3a-hydroxi, 3b-substituerade pregnaner
DE69433663D1 (en) ANTIBODIES AGAINST HUMAN PROSTATE-SPECIFIC GALLIC CALLIC REIN
MXPA03007853A (en) Method for the synthesis of 2 ,3 -dideoxy-2 ,3 -didehydronucleosides.
EP0675904A4 (en) Human neutralizing monoclonal antibodies to human immunodeficiency virus.
TR199901174T2 (en) New heterocyclylmethyl-substituted pyrazole derivatives.
DK517380A (en) HYBRID CELL LINE AND PROCEDURES FOR PRODUCING AND USING THEREOF
NO933179L (en) Anti-idiotype antibodies to human melanoma-associated proteoglycan antigen
ATE512224T1 (en) RECONSTITUTED HUMAN ANTI-HM.1 ANTIBODIES
DE59914538D1 (en) Tetravalent antibody constructs
ES2136760T3 (en) PRODUCTION OF HUMANIZED IMMUNOGLOBULINS AND CORRESPONDING POLYNUCLEOTIDES.
SG6586G (en) Monoclonal antibody to human helper t cells, method of preparing it, hybrid cell line producing it, its diagnostic and therapeutic uses and diagnostic and therapeutic composi
HUP0301235A2 (en) Treatment of central nervous system diseases by antibodies against glatiramer acetate
SE7803280L (en) CONSTRUCTION ELEMENT KIT FOR MANUFACTURE OF VARIABLES, FRAMEWORKS
NO964013D0 (en) Monoclonal antibodies that recognize TIE receptor and their use
DK517280A (en) HYBRID CELL LINE AND PROCEDURES FOR PRODUCING AND USING THEREOF
NO943388L (en) Selective change of antibody immunogenicity
FI895389A0 (en) FOERFARANDE FOER FRAMSTAELLNING AV 3,5-DIMETHYL-4-METOXIPYRIDINDERIVAT SAMT NY MELLANPRODUKT HAERFOER.
BR9708843B1 (en) Diagnostic methods of control loop malfunction.
DK0476226T3 (en) Monoclonal antibody to human IgE
MX9305920A (en) RECONFIGURED MONOCLONAL ANTIBODIES, AGAINST AN IMMUNOGLOBULIN ISOTYPE.
KR900009595A (en) Method for producing 2-chloro-5-chloromethylpyridine
JPS5435870A (en) Exhaust gas denitration method
SE7801930L (en) METHOD OF PREPARING 1,3,5-TRIAZIN-2,6-DIONER
NL7807723A (en) PROCESS FOR THE PREPARATION OF SYNTHESIS GASES BY PARTIAL OXIDATION.
NO952157L (en) Method of producing tear-off cap, as well as tear-off cap made by this method